Search Results - "Witztum, Joseph L."

Statin therapy increases lipoprotein(a) levels by Tsimikas, Sotirios, Gordts, Philip L S M, Nora, Chelsea, Yeang, Calvin, Witztum, Joseph L

“…Abstract Aims Lipoprotein(a) [Lp(a)] is elevated in 20–30% of people. This study aimed to assess the effect of statins on Lp(a) levels. Methods and results…”
Get full text

Innate sensing of oxidation-specific epitopes in health and disease by Binder, Christoph J., Papac-Milicevic, Nikolina, Witztum, Joseph L.

“…Key Points Oxidative stress results in the oxidative damage of membrane lipids, leading to the formation of neo-self epitopes, which are known as…”
Get full text

Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements by Yeang, Calvin, Witztum, Joseph L., Tsimikas, Sotirios

“…Current methods for determining “LDL-C” in clinical practice measure the cholesterol content of both LDL and lipoprotein(a) [Lp(a)-C]. We developed a…”
Get full text

The influence of innate and adaptive immune responses on atherosclerosis by Witztum, Joseph L, Lichtman, Andrew H

“…Both the chronic development of atherosclerotic lesions and the acute changes in lesion phenotype that lead to clinical cardiovascular events are significantly…”
Get full text

An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis by Zhao, Peng, Sun, Xiaoli, Chaggan, Cynthia, Liao, Zhongji, In Wong, Kai, He, Feng, Singh, Seema, Loomba, Rohit, Karin, Michael, Witztum, Joseph L, Saltiel, Alan R

“…Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of the energy sensor adenosine monophosphate (AMP)-activated…”
Get full text

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels by Alexander, Veronica J, Xia, Shuting, Hurh, Eunju, Hughes, Steven G, O’Dea, Louis, Geary, Richard S, Witztum, Joseph L, Tsimikas, Sotirios

“…Abstract Aims Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease. AKCEA-APOCIII-LRx is an…”
Get full text

B Cells and Humoral Immunity in Atherosclerosis by Tsiantoulas, Dimitrios, Diehl, Cody J, Witztum, Joseph L, Binder, Christoph J

“…Insights into the important contribution of inflammation and immune functions in the development and progression of atherosclerosis have greatly improved our…”
Get full text

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis by Tsimikas, Sotirios, Fazio, Sergio, Ferdinand, Keith C., Ginsberg, Henry N., Koschinsky, Marlys L., Marcovina, Santica M., Moriarty, Patrick M., Rader, Daniel J., Remaley, Alan T., Reyes-Soffer, Gissette, Santos, Raul D., Thanassoulis, George, Witztum, Joseph L., Danthi, Simhan, Olive, Michelle, Liu, Lijuan

“…Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease…”
Get full text

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice by Que, Xuchu, Hung, Ming-Yow, Yeang, Calvin, Gonen, Ayelet, Prohaska, Thomas A., Sun, Xiaoli, Diehl, Cody, Määttä, Antti, Gaddis, Dalia E., Bowden, Karen, Pattison, Jennifer, MacDonald, Jeffrey G., Ylä-Herttuala, Seppo, Mellon, Pamela L., Hedrick, Catherine C., Ley, Klaus, Miller, Yury I., Glass, Christopher K., Peterson, Kirk L., Binder, Christoph J., Tsimikas, Sotirios, Witztum, Joseph L.

“…Oxidized phospholipids (OxPL) are ubiquitous, are formed in many inflammatory tissues, including atherosclerotic lesions, and frequently mediate…”
Get full text

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides by Graham, Mark J, Lee, Richard G, Brandt, Teresa A, Tai, Li-Jung, Fu, Wuxia, Peralta, Raechel, Yu, Rosie, Hurh, Eunju, Paz, Erika, McEvoy, Bradley W, Baker, Brenda F, Pham, Nguyen C, Digenio, Andres, Hughes, Steven G, Geary, Richard S, Witztum, Joseph L, Crooke, Rosanne M, Tsimikas, Sotirios

“…Angiopoietin-like 3 (ANGPTL3) inhibits endothelial lipase and lipoprotein lipase. Injection of antisense oligonucleotides targeting ANGPTL3 messenger RNA…”
Get full text

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials by Viney, Nicholas J, BSc, van Capelleveen, Julian C, MD, Geary, Richard S, PhD, Xia, Shuting, MS, Tami, Joseph A, PharmD, Yu, Rosie Z, PhD, Marcovina, Santica M, Prof, Hughes, Steven G, MD, Graham, Mark J, MS, Crooke, Rosanne M, PhD, Crooke, Stanley T, MD, Witztum, Joseph L, Prof, Stroes, Erik S, Prof, Tsimikas, Sotirios, Prof

“…Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific…”
Get full text

Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis by Capoulade, Romain, PhD, Chan, Kwan L., MD, Yeang, Calvin, MD, PhD, Mathieu, Patrick, MD, Bossé, Yohan, PhD, Dumesnil, Jean G., MD, Tam, James W., MD, Teo, Koon K., MBBCh, PhD, Mahmut, Ablajan, MD, MSc, Yang, Xiaohong, BSc, Witztum, Joseph L., MD, Arsenault, Benoit J., PhD, Després, Jean-Pierre, PhD, Pibarot, Philippe, DVM, PhD, Tsimikas, Sotirios, MD

“…Abstract Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification…”
Get full text

Targeting APOC3 in the Familial Chylomicronemia Syndrome by Gaudet, Daniel, Brisson, Diane, Tremblay, Karine, Alexander, Veronica J, Singleton, Walter, Hughes, Steven G, Geary, Richard S, Baker, Brenda F, Graham, Mark J, Crooke, Rosanne M, Witztum, Joseph L

“…In this study, investigators found that APOC3, a key regulator of triglyceride metabolism, had a profound and clinically relevant effect on triglyceride levels…”
Get full text

Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III by Pechlaner, Raimund, MD, PhD, Tsimikas, Sotirios, MD, Yin, Xiaoke, PhD, Willeit, Peter, MD, PhD, Baig, Ferheen, MSc, Santer, Peter, MD, Oberhollenzer, Friedrich, MD, Egger, Georg, MD, Witztum, Joseph L., MD, Alexander, Veronica J., PhD, Willeit, Johann, MD, Kiechl, Stefan, MD, Mayr, Manuel, MD, PhD

“…Abstract Background Routine apolipoprotein (apo) measurements for cardiovascular disease (CVD) are restricted to apoA-I and apoB. Here, the authors measured an…”
Get full text

Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis by Seidman, Jason S., Troutman, Ty D., Sakai, Mashito, Gola, Anita, Spann, Nathanael J., Bennett, Hunter, Bruni, Cassi M., Ouyang, Zhengyu, Li, Rick Z., Sun, Xiaoli, Vu, BaoChau T., Pasillas, Martina P., Ego, Kaori M., Gosselin, David, Link, Verena M., Chong, Ling-Wa, Evans, Ronald M., Thompson, Bonne M., McDonald, Jeffrey G., Hosseini, Mojgan, Witztum, Joseph L., Germain, Ronald N., Glass, Christopher K.

“…Tissue-resident and recruited macrophages contribute to both host defense and pathology. Multiple macrophage phenotypes are represented in diseased tissues,…”
Get full text

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study by Tsimikas, Sotirios, Prof, Viney, Nicholas J, BSc, Hughes, Steven G, MBBS, Singleton, Walter, MD, Graham, Mark J, MS, Baker, Brenda F, PhD, Burkey, Jennifer L, PhD, Yang, Qingqing, MS, Marcovina, Santica M, Prof, Geary, Richard S, PhD, Crooke, Rosanne M, PhD, Witztum, Joseph L, Prof

“…Summary Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower…”
Get full text

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans by van der Valk, Fleur M, Bekkering, Siroon, Kroon, Jeffrey, Yeang, Calvin, Van den Bossche, Jan, van Buul, Jaap D, Ravandi, Amir, Nederveen, Aart J, Verberne, Hein J, Scipione, Corey, Nieuwdorp, Max, Joosten, Leo A.B, Netea, Mihai G, Koschinsky, Marlys L, Witztum, Joseph L, Tsimikas, Sotirios, Riksen, Niels P, Stroes, Erik S.G

“…BACKGROUND:Elevated lipoprotein(a) [Lp(a)] is a prevalent, independent cardiovascular risk factor, but the underlying mechanisms responsible for its…”
Get full text

Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis by Sun, Xiaoli, Seidman, Jason S., Zhao, Peng, Troutman, Ty D., Spann, Nathanael J., Que, Xuchu, Zhou, Fangli, Liao, Zhongji, Pasillas, Martina, Yang, Xiaohong, Magida, Jason A., Kisseleva, Tatiana, Brenner, David A., Downes, Michael, Evans, Ronald M., Saltiel, Alan R., Tsimikas, Sotirios, Glass, Christopher K., Witztum, Joseph L.

“…Oxidized phospholipids (OxPLs), which arise due to oxidative stress, are proinflammatory and proatherogenic, but their roles in non-alcoholic steatohepatitis…”
Get full text

Adaptive immunity in atherogenesis: new insights and therapeutic approaches by Lichtman, Andrew H, Binder, Christoph J, Tsimikas, Sotirios, Witztum, Joseph L

“…Many remarkable advances have improved our understanding of the cellular and molecular events in the pathogenesis of atherosclerosis. Chief among these is the…”
Get full text

Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation by Schnitzler, Johan G., Hoogeveen, Renate M., Ali, Lubna, Prange, Koen H.M., Waissi, Farahnaz, van Weeghel, Michel, Bachmann, Julian C., Versloot, Miranda, Borrelli, Matthew J., Yeang, Calvin, De Kleijn, Dominique P.V., Houtkooper, Riekelt H., Koschinsky, Marlys L., de Winther, Menno P.J., Groen, Albert K., Witztum, Joseph L., Tsimikas, Sotirios, Stroes, Erik S.G., Kroon, Jeffrey

“…Patients with elevated levels of lipoprotein(a) [Lp(a)] are hallmarked by increased metabolic activity in the arterial wall on positron emission…”
Get full text